echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhong Nanshan: The outbreak is likely to continue this winter and next spring

    Zhong Nanshan: The outbreak is likely to continue this winter and next spring

    • Last Update: 2020-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BEIJING, Sept. 18 (Reporter Yu Liyuan) This winter and spring outbreak may continue to exist or develop, found that local outbreaks, the community-level joint prevention and control, community universal nucleic acid screening, tracking close contacts, isolation of nucleic acid-positive asymptomatic patients and other ways are effective.Nanshan, head of the expert group of the Scientific Research And Research Group of the Joint Prevention and Control Mechanism and director of the National Center for Clinical Medicine of Respiratory Diseases, made the above statement at the Global Forum on Science and Life Health held on the 18th.
    The Global Forum on Science and Life Health is one of the parallel forums of the 2020 Zhongguancun Forum, where scientists from all over the world share experiences in anti-epidemic and scientific research, and discuss topics such as vaccine research and development, drug screening and clinical treatment, pathogens and transmission pathways, and testing reagents.
    , according to Zhong Nanshan, mass vaccination to form a group immune barrier will take time. China's vaccine has completed phase I and II clinical trials, and four vaccines have entered Phase III clinical trials.
    Zhong Nanshan said that China and more than 40 countries around the world to carry out new coronary pneumonia vaccine cooperation, has been approved in Brazil, Indonesia, the United Arab Emirates, Russia, Peru, Argentina, Morocco and other countries for clinical phase III trials, four vaccines have entered the clinical phase III trial phase with international cooperation.
    ,
    military medical school, said the virus mutation had no significant effect on vaccine effectiveness. Six recombined new crown vaccines, from China, Russia, the United Kingdom, the United States and Germany, have been compared for safety.
    , China's minister of science and technology, revealed that 11 new coronary pneumonia vaccines have entered clinical trials, four of which have entered Phase III clinical trials.
    According to Wang Zhigang, since the outbreak, China's scientific and technological community and scientific researchers have invested fully in epidemic prevention and control research, focusing on drug screening, vaccine research and development, testing technology, viral pathogens and epidemiology, animal models and other five key directions, rapid screening and evaluation of a number of effective treatment drugs and treatment methods, the formation of treatment methods suitable for patients at different stages.
    At the same time, Chinese science and technology personnel in a short period of time completed nucleic acid testing, anti-medical reagents and supporting equipment research and development, to meet the testing needs of different applications, parallel promotion of inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, nucleic acid vaccines, anti-virus influenza vaccines and other 5 technical routes of research and development.
    Wang Zhigang said that the current outbreak of neo-crown pneumonia is still spreading around the world, has not yet been fully controlled, with the arrival of autumn and winter this year, the outbreak is still possible to rebound, the situation of prevention and control is still serious.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.